<p>Thurston Springer Miller Herd</p>
<p>&amp; Titak Inc. 在第二季度增持了约翰逊公司（NYSE:JNJ - 免费报告）23.2% 的股份，根据其最近向 SEC 的披露。该基金在此期间购买了额外的 5,277 股后，持有该公司 28,009 股股票。根据其最近向 SEC 的备案，Thurston Springer Miller Herd</p>
<p>&amp; Titak Inc. 在约翰逊公司的持股价值为 4,279,000 美元。</p>
<p>获取 <strong>约翰逊公司</strong> 的提醒：</p>
<ul>
<li>随着市场轮动，这只医疗保健 ETF 引领潮流</li>
</ul>
<p>其他一些大型投资者也对 JNJ 的持仓进行了调整。Nuveen LLC 在第一季度新建了约 1,369,188,000 美元的约翰逊公司股份。GAMMA Investing LLC 在第一季度将其在约翰逊公司的持仓提高了 24,450.4%。GAMMA Investing LLC 目前拥有 7,215,367 股该公司的股票，价值 1,196,596,000 美元，此前在上个季度购买了额外的 7,185,977 股。纽约梅隆银行在第一季度将其在约翰逊公司的持仓提高了 26.4%。纽约梅隆银行目前拥有 23,182,464 股该公司的股票，价值 3,844,580,000 美元，此前在上个季度购买了额外的 4,842,582 股。Pacer Advisors Inc.在第一季度将其在约翰逊公司的持仓提高了 1,382.0%。Pacer Advisors Inc.目前拥有 3,030,084 股该公司的股票，价值 502,509,000 美元，此前在上个季度购买了额外的 2,825,626 股。最后，Universal Beteiligungs und Servicegesellschaft mbH 在第四季度新建了约 349,206,000 美元的约翰逊公司股份。机构投资者和对冲基金持有该公司 69.55% 的股份。</p>
<h2>约翰逊公司的内部交易</h2>
<p>在其他关于约翰逊公司的新闻中，执行副总裁 Jennifer L. Taubert 于 9 月 4 日星期四出售了 56,471 股该公司的股票。股票以平均价格 177.81 美元出售，总价值为 10,041,108.51 美元。交易后，该执行副总裁直接持有 178,013 股该公司的股票，估值约为 31,652,491.53 美元。这笔交易代表了他们持股的 24.08% 的减少。该出售在向证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站访问。内部人士持有该公司 0.16% 的股份。</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>JNJ 股票的上涨表明对新增长路径的信心</li>
</ul>
<p>几位研究分析师最近对 JNJ 股票发布了报告。Piper Sandler 在 7 月 17 日的研究报告中重新给予约翰逊公司 “增持” 评级。Guggenheim 在 7 月 17 日的研究报告中重申了 “中性” 评级，并将约翰逊公司的目标价设定为 167.00 美元（上调自 164.00 美元）。花旗集团在 8 月 21 日的研究报告中将约翰逊公司的目标价从 185.00 美元上调至 200.00 美元，并给予该股票 “买入” 评级。摩根士丹利在 7 月 17 日的研究报告中将约翰逊公司的目标价从 171.00 美元上调至 176.00 美元，并给予该股票 “同等权重” 评级。最后，Erste Group Bank 在 7 月 23 日的研究报告中将约翰逊公司的评级从 “持有” 上调至 “买入”。两位研究分析师给予该股票 “强烈买入” 评级，九位分析师给予 “买入” 评级，九位分析师给予 “持有” 评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，平均目标价为 176.29 美元。</p>
<p><strong>阅读我们最新的 JNJ 股票分析</strong></p>
<h2>约翰逊公司的价格表现</h2>
<ul>
<li>3 个强劲收益支撑的高分红股票</li>
</ul>
<p>JNJ 在周五开盘价为 178.10 美元。约翰逊公司的年内最低价为 140.68 美元，年内最高价为 181.16 美元。该公司的债务与股本比率为 0.50，流动比率为 1.01，速动比率为 0.76。该公司的 50 日简单移动平均线为 170.81 美元，200 日简单移动平均线为 161.29 美元。该股票的市值为 4289.3 亿美元，市盈率为 19.05，市盈增长比率为 2.27，贝塔值为 0.40。</p>
<p>约翰逊公司（NYSE:JNJ - 获取免费报告）最近于 7 月 16 日星期三发布了季度财报。该公司报告季度每股收益为 2.77 美元，超出市场共识预期的 2.68 美元，超出 0.09 美元。约翰逊公司的净利润率为 25.00%，股本回报率为 32.49%。该公司在本季度的收入为 237.4 亿美元，而分析师预期为 228.5 亿美元。在去年同期，该公司每股收益为 2.82 美元。与去年同期相比，约翰逊公司的收入增长了 5.8%。约翰逊公司将其 2025 财年的每股收益指导设定在 10.800-10.900 美元。卖方分析师预计约翰逊公司在当前财年将发布 10.58 美元的每股收益。</p>
<h2>约翰逊公司的分红公告</h2>
<p>该公司还最近披露了季度分红，于 9 月 9 日星期二支付。8 月 26 日的股东获得了 1.30 美元的分红。该分红的除息日为 8 月 26 日。这代表着年化分红为 5.20 美元，收益率为 2.9%。约翰逊公司的分红支付比率（DPR）目前为 55.61%。</p>
<h2>关于约翰逊公司</h2>
<p>（免费报告）</p>
<p>约翰逊公司是一家控股公司，专注于医疗领域的产品研究、开发、制造和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票超过强生</li>
<li>交易股票：相对强弱指数及其用途</li>
<li>乘着奢侈零售浪潮，这三只高端品牌股票值得关注</li>
<li>股息捕捉策略：你需要知道的事项</li>
<li>华尔街悄然重注这些中国科技巨头</li>
<li>三只股票引领表情包股票复兴</li>
<li>Meta 的 6000 亿美元美国投资：对股票是看跌还是看涨？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在强生吗？</h2>
<p>在考虑强生之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而强生并不在名单上。</p>
<p>虽然强生目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

强生

<p>Thurston Springer Miller Herd & Titak Inc. 在第二季度将其在强生（NYSE: JNJ）的持股增加了 23.2%，目前持有 28,009 股，价值 428 万美元。其他投资者，包括 Nuveen LLC 和 GAMMA Investing LLC，也显著调整了他们的持仓。内部人士 Jennifer L. Taubert 出售了 56,471 股，减少了 24.08% 的持股比例。分析师对 JNJ 维持 “适度买入” 的共识，目标价为 176.29 美元。JNJ 的股票开盘价为 178.10 美元，市值为 4289.3 亿美元，市盈率为 19.05</p>

<p>Thurston Springer Miller Herd &amp; Titak Inc. grew its stake in shares of Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 23.2% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 28,009 shares of the company's stock after buying an additional 5,277 shares during the period. Thurston Springer Miller Herd &amp; Titak Inc.'s holdings in Johnson &amp; Johnson were worth $4,279,000 as of its most recent filing with the SEC.</p>
<div class="lb-trans"><p>Thurston Springer Miller Herd</p>
<p>&amp; Titak Inc. 在第二季度增持了约翰逊公司（NYSE:JNJ - 免费报告）23.2% 的股份，根据其最近向 SEC 的披露。该基金在此期间购买了额外的 5,277 股后，持有该公司 28,009 股股票。根据其最近向 SEC 的备案，Thurston Springer Miller Herd</p>
<p>&amp; Titak Inc. 在约翰逊公司的持股价值为 4,279,000 美元。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>约翰逊公司</strong> 的提醒：</p>
</div><ul>
<li>As the Market Rotates, This Healthcare ETF Is Leading the Way</li>
</ul>
<div class="lb-trans"><ul>
<li>随着市场轮动，这只医疗保健 ETF 引领潮流</li>
</ul>
</div><p>A number of other large investors have also made changes to their positions in JNJ. Nuveen LLC acquired a new position in Johnson &amp; Johnson in the first quarter worth about $1,369,188,000. GAMMA Investing LLC raised its position in Johnson &amp; Johnson by 24,450.4% in the first quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company's stock worth $1,196,596,000 after purchasing an additional 7,185,977 shares in the last quarter. Bank of New York Mellon Corp raised its position in Johnson &amp; Johnson by 26.4% in the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock worth $3,844,580,000 after purchasing an additional 4,842,582 shares in the last quarter. Pacer Advisors Inc. raised its position in Johnson &amp; Johnson by 1,382.0% in the first quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company's stock worth $502,509,000 after purchasing an additional 2,825,626 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Johnson &amp; Johnson in the fourth quarter worth about $349,206,000. Institutional investors and hedge funds own 69.55% of the company's stock.</p>
<div class="lb-trans"><p>其他一些大型投资者也对 JNJ 的持仓进行了调整。Nuveen LLC 在第一季度新建了约 1,369,188,000 美元的约翰逊公司股份。GAMMA Investing LLC 在第一季度将其在约翰逊公司的持仓提高了 24,450.4%。GAMMA Investing LLC 目前拥有 7,215,367 股该公司的股票，价值 1,196,596,000 美元，此前在上个季度购买了额外的 7,185,977 股。纽约梅隆银行在第一季度将其在约翰逊公司的持仓提高了 26.4%。纽约梅隆银行目前拥有 23,182,464 股该公司的股票，价值 3,844,580,000 美元，此前在上个季度购买了额外的 4,842,582 股。Pacer Advisors Inc.在第一季度将其在约翰逊公司的持仓提高了 1,382.0%。Pacer Advisors Inc.目前拥有 3,030,084 股该公司的股票，价值 502,509,000 美元，此前在上个季度购买了额外的 2,825,626 股。最后，Universal Beteiligungs und Servicegesellschaft mbH 在第四季度新建了约 349,206,000 美元的约翰逊公司股份。机构投资者和对冲基金持有该公司 69.55% 的股份。</p>
</div><h2>Insider Transactions at Johnson &amp; Johnson</h2>
<div class="lb-trans"><h2>约翰逊公司的内部交易</h2>
</div><p>In other Johnson &amp; Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Insiders own 0.16% of the company's stock.</p>
<div class="lb-trans"><p>在其他关于约翰逊公司的新闻中，执行副总裁 Jennifer L. Taubert 于 9 月 4 日星期四出售了 56,471 股该公司的股票。股票以平均价格 177.81 美元出售，总价值为 10,041,108.51 美元。交易后，该执行副总裁直接持有 178,013 股该公司的股票，估值约为 31,652,491.53 美元。这笔交易代表了他们持股的 24.08% 的减少。该出售在向证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站访问。内部人士持有该公司 0.16% 的股份。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>JNJ Stock Surge Signals Confidence in New Growth Path</li>
</ul>
<div class="lb-trans"><ul>
<li>JNJ 股票的上涨表明对新增长路径的信心</li>
</ul>
</div><p>Several research analysts recently issued reports on JNJ shares. Piper Sandler reissued an &#34;overweight&#34; rating on shares of Johnson &amp; Johnson in a research report on Thursday, July 17th. Guggenheim reaffirmed a &#34;neutral&#34; rating and set a $167.00 price objective (up from $164.00) on shares of Johnson &amp; Johnson in a research note on Thursday, July 17th. Citigroup upped their price objective on shares of Johnson &amp; Johnson from $185.00 to $200.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, August 21st. Morgan Stanley upped their price objective on shares of Johnson &amp; Johnson from $171.00 to $176.00 and gave the stock an &#34;equal weight&#34; rating in a research note on Thursday, July 17th. Finally, Erste Group Bank raised shares of Johnson &amp; Johnson from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Wednesday, July 23rd. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $176.29.</p>
<div class="lb-trans"><p>几位研究分析师最近对 JNJ 股票发布了报告。Piper Sandler 在 7 月 17 日的研究报告中重新给予约翰逊公司 “增持” 评级。Guggenheim 在 7 月 17 日的研究报告中重申了 “中性” 评级，并将约翰逊公司的目标价设定为 167.00 美元（上调自 164.00 美元）。花旗集团在 8 月 21 日的研究报告中将约翰逊公司的目标价从 185.00 美元上调至 200.00 美元，并给予该股票 “买入” 评级。摩根士丹利在 7 月 17 日的研究报告中将约翰逊公司的目标价从 171.00 美元上调至 176.00 美元，并给予该股票 “同等权重” 评级。最后，Erste Group Bank 在 7 月 23 日的研究报告中将约翰逊公司的评级从 “持有” 上调至 “买入”。两位研究分析师给予该股票 “强烈买入” 评级，九位分析师给予 “买入” 评级，九位分析师给予 “持有” 评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，平均目标价为 176.29 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on JNJ</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 JNJ 股票分析</strong></p>
</div><h2>Johnson &amp; Johnson Price Performance</h2>
<div class="lb-trans"><h2>约翰逊公司的价格表现</h2>
</div><ul>
<li>3 Big Dividend Plays With Strong Earnings to Back Them</li>
</ul>
<div class="lb-trans"><ul>
<li>3 个强劲收益支撑的高分红股票</li>
</ul>
</div><p>JNJ opened at $178.10 on Friday. Johnson &amp; Johnson has a one year low of $140.68 and a one year high of $181.16. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company's 50 day simple moving average is $170.81 and its 200-day simple moving average is $161.29. The stock has a market capitalization of $428.93 billion, a P/E ratio of 19.05, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40.</p>
<div class="lb-trans"><p>JNJ 在周五开盘价为 178.10 美元。约翰逊公司的年内最低价为 140.68 美元，年内最高价为 181.16 美元。该公司的债务与股本比率为 0.50，流动比率为 1.01，速动比率为 0.76。该公司的 50 日简单移动平均线为 170.81 美元，200 日简单移动平均线为 161.29 美元。该股票的市值为 4289.3 亿美元，市盈率为 19.05，市盈增长比率为 2.27，贝塔值为 0.40。</p>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson &amp; Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same period in the prior year, the firm earned $2.82 earnings per share. Johnson &amp; Johnson's revenue was up 5.8% compared to the same quarter last year. Johnson &amp; Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Sell-side analysts anticipate that Johnson &amp; Johnson will post 10.58 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>约翰逊公司（NYSE:JNJ - 获取免费报告）最近于 7 月 16 日星期三发布了季度财报。该公司报告季度每股收益为 2.77 美元，超出市场共识预期的 2.68 美元，超出 0.09 美元。约翰逊公司的净利润率为 25.00%，股本回报率为 32.49%。该公司在本季度的收入为 237.4 亿美元，而分析师预期为 228.5 亿美元。在去年同期，该公司每股收益为 2.82 美元。与去年同期相比，约翰逊公司的收入增长了 5.8%。约翰逊公司将其 2025 财年的每股收益指导设定在 10.800-10.900 美元。卖方分析师预计约翰逊公司在当前财年将发布 10.58 美元的每股收益。</p>
</div><h2>Johnson &amp; Johnson Dividend Announcement</h2>
<div class="lb-trans"><h2>约翰逊公司的分红公告</h2>
</div><p>The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. Johnson &amp; Johnson's dividend payout ratio (DPR) is presently 55.61%.</p>
<div class="lb-trans"><p>该公司还最近披露了季度分红，于 9 月 9 日星期二支付。8 月 26 日的股东获得了 1.30 美元的分红。该分红的除息日为 8 月 26 日。这代表着年化分红为 5.20 美元，收益率为 2.9%。约翰逊公司的分红支付比率（DPR）目前为 55.61%。</p>
</div><h2>About Johnson &amp; Johnson</h2>
<div class="lb-trans"><h2>关于约翰逊公司</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p>
<div class="lb-trans"><p>约翰逊公司是一家控股公司，专注于医疗领域的产品研究、开发、制造和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>Trading Stocks: RSI and Why it's Useful</li>
<li>Ride the Luxury Retail Wave with These 3 High-End Brand Stocks</li>
<li>Dividend Capture Strategy: What You Need to Know</li>
<li>Wall Street Quietly Bets Big on These Chinese Tech Giants</li>
<li>3 Tickers Leading a Meme Stock Revival</li>
<li>Meta's $600B U.S. Investment: Bearish or Bullish for Shares?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过强生</li>
<li>交易股票：相对强弱指数及其用途</li>
<li>乘着奢侈零售浪潮，这三只高端品牌股票值得关注</li>
<li>股息捕捉策略：你需要知道的事项</li>
<li>华尔街悄然重注这些中国科技巨头</li>
<li>三只股票引领表情包股票复兴</li>
<li>Meta 的 6000 亿美元美国投资：对股票是看跌还是看涨？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在强生吗？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑强生之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而强生并不在名单上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然强生目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Thurston Springer Miller Herd & Titak Inc. 在强生公司拥有 428 万美元的持仓